{"id":26,"date":"2012-03-08T20:13:49","date_gmt":"2012-03-08T11:13:49","guid":{"rendered":"http:\/\/urology.dept.med.gunma-u.ac.jp\/?p=26"},"modified":"2018-08-27T10:56:19","modified_gmt":"2018-08-27T01:56:19","slug":"2009paper","status":"publish","type":"post","link":"https:\/\/urology.dept.med.gunma-u.ac.jp\/?p=26","title":{"rendered":"2009\u5e74"},"content":{"rendered":"
    \n
  1. Ito K\uff1aProstate-specific antigen-based screening for prostate cancer :Evidence, controversies and future perspectives. Int J Urol; 16(5):458-464, 2009.<\/li>\n
  2. Ito K\uff1aControversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues. Int J Urol; 16(9):711-712, 2009.<\/li>\n
  3. Ito K\uff1aWords of wisdom. Re:Mortality results from a randomized prostate-cancer screening trial. Eur Urol; 56(4):743-744, 2009.<\/li>\n
  4. Okamura K, Koike H, Sekine Y, Matsui H and Suzuki K\uff1aSurvivin and its spliced isoform gene expression is associated with proliferation of renal cancer cells and clinical stage of renal cancer. Cancer Epidemiology; 33(2):137-141, 2009.<\/li>\n
  5. Miyakubo M, Ito K, Yamamoto T, Takechi H, Ohi M and Suzuki K\uff1aProprostate-specific antigen :Its usefulness in the era of multiple-core prostate biopsy. Int J Urol; 16(6):561-565, 2009.<\/li>\n
  6. Abdulah R, Faried A, Kobayashi K, Yamazaki C, Suradji EW, Ito K, Suzuki K, Murakami M, Kuwano H and Koyama H\uff1aSelenium enrichment of broccoli sprout extract increases chemosensitivity and apoptosis of LNCaP prostate cancer cells. BMC Cancer; 9:414, 2009.<\/li>\n
  7. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR and Akaza H\uff1aRisk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol; 27(26):4306-4313, 2009.<\/li>\n
  8. Sekine Y, Koike H, Nakano T, Nakajima K Takahashi S and Suzuki K\uff1aRemnant lipoproteins induced proliferation of human prostate cancer cell, PC-3 but not LNCaP, via low density lipoprotein receptor. Cancer Epidemiology; 33:16-23, 2009.<\/li>\n
  9. \u4f0a\u85e4\u4e00\u4eba\u3001\u8d64\u5009\u529f\u4e00\u90ce\u3001\u5c71\u672c\u3000\u5de7\u3001\u7530\u4e2d\u5553\u5e79\u3001\u5cf6\u5d0e\u3000\u6df3\u3001\u5c71\u4e2d\u82f1\u58fd\uff1a\u524d\u7acb\u817a\u304c\u3093\u691c\u8a3a\u7814\u7a76\uff08\u7530\u4e2d\u73ed\uff09\u306e\u6982\u8981\u30fb\u30b3\u30f3\u30bb\u30d7\u30c8. \u65e5\u672c\u304c\u3093\u691c\u8a3a\u30fb\u8a3a\u65ad\u5b66\u4f1a\u8a8c; 16(3):102-106, 2009.<\/li>\n
  10. \u4f0a\u85e4\u4e00\u4eba\uff1a\u672c\u90a6\u306b\u304a\u3051\u308b\u9069\u5207\u306a\u524d\u7acb\u817a\u304c\u3093\u691c\u8a3a\u30b7\u30b9\u30c6\u30e0\u306e\u63d0\u6848. \u65e5\u672c\u814e\u6ccc\u5c3f\u5668\u75be\u60a3\u4e88\u9632\u533b\u5b66\u7814\u7a76\u4f1a\u8a8c; 17(1):32-35, 2009.<\/li>\n
  11. \u4f0a\u85e4\u4e00\u4eba\uff1a\u65e5\u672c\u4eba\u7537\u6027\u306b\u5bfe\u3057\u3066\u524d\u7acb\u817a\u304c\u3093\u691c\u8a3a\u306f\u63a8\u5968\u3055\u308c\u308b\u304b\uff1f. EBM: \u6ccc\u5c3f\u5668\u75be\u60a3\u306e\u6cbb\u7642; pp.1-8, \u4e2d\u5916\u533b\u5b66\u793e. 2009.<\/li>\n
  12. \u4f0a\u85e4\u4e00\u4eba\uff1a\u524d\u7acb\u817a\u304c\u3093\u691c\u8a3a\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3. \u6210\u4eba\u75c5\u3068\u751f\u6d3b\u7fd2\u6163\u75c5; 39(6):707-712, 2009.<\/li>\n
  13. \u4f0a\u85e4\u4e00\u4eba\uff1a\u6b27\u7c73\u3068\u65e5\u672c\u3067\u9032\u884c\u4e2d\u306e\u524d\u7acb\u817a\u304c\u3093\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u7814\u7a76\u306e\u5c55\u671b. \u6ccc\u5c3f\u5668\u5916\u79d1; 22(8):959-961, 2009.<\/li>\n
  14. \u4f0a\u85e4\u4e00\u4eba\u3001\u8d64\u5009\u529f\u4e00\u90ce\u3001\u5c71\u672c\u3000\u5de7\u3001\u7530\u4e2d\u5553\u5e79\u3001\u5cf6\u5d0e\u3000\u6df3\u3001\u5c71\u4e2d\u82f1\u58fd\uff1a\u300c\u524d\u7acb\u817a\u691c\u8a3a\u5354\u8b70\u4f1a\u904b\u55b6\u59d4\u54e1\u4f1a\u30fb\u524d\u7acb\u817a\u304c\u3093\u64b2\u6ec5\u63a8\u9032\u59d4\u54e1\u4f1a\u5408\u540c\u4f1a\u8b70\u3000\u8a18\u9332\u96c6\u300d\uff1a\u524d\u7acb\u817a\u304c\u3093\u691c\u8a3a\u7814\u7a76\u73ed\uff08\u7530\u4e2d\u73ed\uff09\u306e\u6982\u8981\u30fb\u9032\u6357\u72b6\u6cc1\u3000\uff11\uff09\u6982\u8981\u30fb\u30b3\u30f3\u30bb\u30d7\u30c8. \u6ccc\u5c3f\u5668\u5916\u79d1; 22(8):1107-1110, 2009.<\/li>\n
  15. \u4f0a\u85e4\u4e00\u4eba\u3001\u5bae\u4e45\u4fdd\u771f\u610f\u3001\u5c0f\u6797\u5e79\u7537\u3001\u7af9\u6fa4\u3000\u8c4a\u3001\u53e4\u4f5c\u3000\u671b\u3001\u677e\u672c\u548c\u4e45\u3001\u5c71\u672c\u3000\u5de7\u3001\u6b66\u667a\u6d69\u4e4b\u3001\u767b\u4e38\u884c\u96c4\u3001\u9234\u6728\u548c\u6d69\uff1a\u300c\u524d\u7acb\u817a\u691c\u8a3a\u5354\u8b70\u4f1a\u904b\u55b6\u59d4\u54e1\u4f1a\u30fb\u524d\u7acb\u817a\u304c\u3093\u64b2\u6ec5\u63a8\u9032\u59d4\u54e1\u4f1a\u5408\u540c\u4f1a\u8b70\u3000\u8a18\u9332\u96c6\u300d\uff1a\u524d\u7acb\u817a\u304c\u3093\u691c\u8a3a\u7814\u7a76\u73ed\uff08\u7530\u4e2d\u73ed\uff09\u306e\u6982\u8981\u30fb\u9032\u6357\u72b6\u6cc1\u3000\uff12\uff09\u7fa4\u99ac\u30bb\u30af\u30b7\u30e7\u30f3\u306e\u9032\u6357\u72b6\u6cc1. \u6ccc\u5c3f\u5668\u5916\u79d1; 22(8):1111-1113, 2009.<\/li>\n
  16. \u4f0a\u85e4\u4e00\u4eba\u3001\u5bae\u4e45\u4fdd\u771f\u610f\u3001\u5c0f\u6797\u5e79\u7537\u3001\u7af9\u6fa4\u3000\u8c4a\u3001\u53e4\u4f5c\u3000\u671b\u3001\u677e\u672c\u548c\u4e45\u3001\u5c71\u672c\u3000\u5de7\u3001\u6b66\u667a\u6d69\u4e4b\u3001\u767b\u4e38\u884c\u96c4\u3001\u9234\u6728\u548c\u6d69\uff1aJapanese Prospective Cohort Study of Screening for Prostate Cancer (JPSPC): \u7fa4\u99ac\u30bb\u30af\u30b7\u30e7\u30f3\u306b\u304a\u3051\u308b\u521d\u671f\u7d50\u679c. \u6ccc\u5c3f\u5668\u5916\u79d1; 22(8):1021-1022, 2009.<\/li>\n
  17. \u4f0a\u85e4\u4e00\u4eba\u3001\u5bae\u4e45\u4fdd\u771f\u610f\u3001\u5c71\u672c\u3000\u5de7\uff1a\u524d\u7acb\u817a\u816b\u760d\u30de\u30fc\u30ab\u30fc. \u8a3a\u65ad\u3068\u6cbb\u7642; 97(9):1950-1954, 2009.<\/li>\n
  18. \u4f0a\u85e4\u4e00\u4eba\uff1aPSA \u691c\u8a3a\u306e\u6700\u65b0\u60c5\u5831\u2015\u691c\u67fb\u306e\u30bf\u30a4\u30df\u30f3\u30b0\u3068\u691c\u67fb\u5024\u306e\u8aad\u307f\u65b9\u2015. 2009 SRL\u5b9d\u51fd\u3000\u7b2c\uff15\u56deSRL Update Forum\u8b1b\u6f14\u96c6; pp.4-9, 2009.<\/li>\n
  19. \u4f0a\u85e4\u4e00\u4eba\uff1a\u30d6\u30ec\u30a4\u30ad\u30f3\u30b0\u30fb\u30cb\u30e5\u30fc\u30b9\u3000\u524d\u7acb\u817a\u764c\u691c\u8a3a\u306e\u6b7b\u4ea1\u7387\u4f4e\u4e0b\u52b9\u679c\u304c\u660e\u3089\u304b\u306b. 2009 SRL\u5b9d\u51fd\u3000\u7b2c\uff15\u56deSRL Update Forum\u8b1b\u6f14\u96c6; pp.10-14, 2009.<\/li>\n
  20. \u52a0\u85e4\u6625\u96c4\u3001\u5c0f\u6797\u5927\u5fd7\u6717\u3001\u5869\u91ce\u662d\u5f66\u3001\u753a\u7530\u660c\u5df3\u3001\u7267\u91ce\u6b66\u96c4\u3001\u67f4\u5c71\u52dd\u592a\u90ce\u3001\u672c\u9593\u3000\u5b66\uff1a\u8180\u80f1\u826f\u6027\u816b\u760d\u3068\u9451\u5225\u56f0\u96e3\u3067\u3042\u3063\u305f\u597d\u9178\u7403\u6027\u8180\u80f1\u708e\u306e\uff11\u4f8b. \u6ccc\u5c3f\u5668\u5916\u79d1; 22(11):1431-1433, 2009.<\/li>\n
  21. \u718a\u5742\u6587\u6210\u3001\u52a0\u702c\u5609\u660e\u3001\u5c71\u4e2d\u82f1\u58fd\u3001\u5cf6\u7530\u548c\u5b50\u3001\u677e\u672c\u623f\u6c5f\u3001\u77f3\u4e95\u79c0\u548c\u3001\u5c0f\u5009\u6cbb\u4e4b\u3001\u5fb3\u6c38\u3000\u5353\u3001\u5927\u4e95\u3000\u52dd\u3001\u5ee3\u91ce\u6b63\u6cd5\u3001\u9ed2\u6fa4\u3000\u529f\u3001\u4f0a\u85e4\u4e00\u4eba\u3001\u5c71\u672c\u3000\u5de7\u3001\u9234\u6728\u548c\u6d69\uff1a\u9ed2\u6ca2\u75c5\u9662\u9ad8\u5d0e\u5065\u5eb7\u7ba1\u7406\u30bb\u30f3\u30bf\u30fc\u306b\u304a\u3051\u308b\u4eba\u9593\u30c9\u30c3\u30af\u524d\u7acb\u817a\u304c\u3093PSA\u691c\u8a3a\u306e2002\uff5e2006\u5e74\u306e5\u5e74\u9593\u306e\u307e\u3068\u3081. \u7fa4\u99ac\u533b\u5b66; 90:71-75, 2009.<\/li>\n
  22. \u5c0f\u6c60\u79c0\u548c\uff1a\u524d\u7acb\u817a\u764c\u306e\u5897\u6b96\u306b\u95a2\u3059\u308b\u57fa\u790e\u7814\u7a76. Kitakanto Med J; 59(1):113-114, 2009.<\/li>\n
  23. \u7530\u6751\u82b3\u7f8e\u3001\u5c0f\u5c4b\u667a\u5b50\u3001\u68ee\u7530\u5d07\u5f18\u3001\u4e45\u4fdd\u7530\u88d5\u3001\u9ad8\u6a4b\u3000\u4fee\u3001\u85e4\u585a\u3000\u52f2\u3001\u4f0a\u85e4\u4e00\u4eba\u3001\u9234\u6728\u548c\u6d69\uff1a\u5229\u6839\u4e2d\u592e\u75c5\u9662\u306b\u304a\u3051\u308b\u524d\u7acb\u817a\u764c\u75c7\u4f8b\u306e\u81e8\u5e8a\u7684\u691c\u8a0e\u3000\uff0dPSA\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u53d7\u8a3a\u6b74\u306e\u6709\u7121\u306b\u3088\u308b\u751f\u5b58\u7387\u306e\u6bd4\u8f03\uff0d. \u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u96d1\u8a8c; 100(4):525-533, 2009.<\/li>\n
  24. \u91ce\u6751\u660c\u53f2\u3001\u5c0f\u6c60\u79c0\u548c\u3001\u677e\u4e95\u3000\u535a\u3001\u67f4\u7530\u5eb7\u535a\u3001\u7fbd\u9ce5\u57fa\u660e\u3001\u4f0a\u85e4\u4e00\u4eba\u3001\u5c0f\u6797\u5e79\u7537\u3001\u9234\u6728\u548c\u6d69\uff1a\u9ad8\u9f62\u8005\u306e\u814e\u7d30\u80de\u764c\u306b\u5bfe\u3059\u308b\u4f53\u8154\u93e1\u4e0b\u814e\u6458\u9664\u8853\u306e\u691c\u8a0e. Kitakanto Med J; 59(4):333-336, 2009.<\/li>\n
  25. \u5bae\u4e45\u4fdd\u771f\u610f\u3001\u4f0a\u85e4\u4e00\u4eba\u3001\u5c0f\u6797\u5e79\u7537\u3001\u7af9\u6fa4\u3000\u8c4a\u3001\u53e4\u4f5c\u3000\u671b\u3001\u677e\u672c\u548c\u4e45\u3001\u5c71\u672c\u3000\u5de7\u3001\u6b66\u667a\u6d69\u4e4b\u3001\u767b\u4e38\u884c\u96c4\u3001\u9234\u6728\u548c\u6d69\uff1aJapanese Prospective Cohort Study of Screening for Prostate Cancer (JPSPC):\u7814\u7a76\u306e\u30b3\u30f3\u30bb\u30d7\u30c8\u3068\u7fa4\u99ac\u30bb\u30af\u30b7\u30e7\u30f3\u306b\u304a\u3051\u308b\u691c\u8a3a\u53d7\u8a3a\u306e\u30b3\u30f3\u30d7\u30e9\u30a4\u30a2\u30f3\u30b9\u3068\u30b3\u30f3\u30bf\u30df\u30cd\u30fc\u30b7\u30e7\u30f3\u3001\u767a\u898b\u764c\u75c7\u4f8b\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u65e5\u672c\u814e\u6ccc\u5c3f\u5668\u75be\u60a3\u4e88\u9632\u533b\u5b66\u7814\u7a76\u4f1a\u8a8c; 17(1):83-86, 2009.<\/li>\n
  26. \u5c71\u672c\u3000\u5de7\u3001\u4f0a\u85e4\u4e00\u4eba\u3001\u6b66\u667a\u6d69\u4e4b\u3001\u5927\u4e95\u3000\u52dd\u3001\u5bae\u4e45\u4fdd\u771f\u610f\u3001\u9234\u6728\u548c\u6d69\uff1a\u524d\u7acb\u817a\u591a\u6570\u30ab\u6240\u751f\u691c\u9670\u6027\u75c7\u4f8b\u306e\u9577\u671f\u7d4c\u904e\u89b3\u5bdf. \u65e5\u672c\u814e\u6ccc\u5c3f\u5668\u75be\u60a3\u4e88\u9632\u533b\u5b66\u7814\u7a76\u4f1a\u8a8c; 17(1):74-76, 2009.<\/li>\n
  27. \u5c71\u672c\u3000\u5de7\u3001\u4f0a\u85e4\u4e00\u4eba\u3001\u6b66\u667a\u6d69\u4e4b\u3001\u5bae\u4e45\u4fdd\u771f\u610f\u3001\u5927\u4e95\u3000\u52dd\u3001\u5c71\u4e2d\u82f1\u58fd\uff1aPSA 10ng\/ml\u672a\u6e80\u3067\u306epro PSA\u306e\u524d\u7acb\u817a\u764c\u8a3a\u65ad\u306b\u304a\u3051\u308b\u6709\u7528\u6027. \u6ccc\u5c3f\u5668\u5916\u79d1; 22(8):995-996, 2009.<\/li>\n
  28. \u5c71\u672c\u3000\u5de7\u3001\u5c71\u4e2d\u82f1\u58fd\u3001\u6751\u4e95\u3000\u52dd\u3001\u5cf6\u5d0e\u3000\u6df3\u3001\u4f0a\u85e4\u4e00\u4eba\u3001\u8d64\u5009\u529f\u4e00\u90ce\uff1a\u300c\u524d\u7acb\u817a\u691c\u8a3a\u5354\u8b70\u4f1a\u904b\u55b6\u59d4\u54e1\u4f1a\u30fb\u524d\u7acb\u817a\u304c\u3093\u64b2\u6ec5\u63a8\u9032\u59d4\u54e1\u4f1a\u5408\u540c\u4f1a\u8b70\u3000\u8a18\u9332\u96c6\u300d\uff1a\u4eba\u9593\u30c9\u30c3\u30af\u65bd\u8a2d\u306b\u304a\u3051\u308b\u524d\u7acb\u817a\u304c\u3093\u691c\u8a3a\u30a2\u30f3\u30b1\u30fc\u30c8\u96c6\u8a08\u5831\u544a\uff0d\u5e73\u621019\u5e74\u5ea6\uff0d. \u6ccc\u5c3f\u5668\u5916\u79d1; 22(8):1103-1106, 2009.<\/li>\n
  29. \u7530\u4e2d\u5553\u5e79\u3001\u4f0a\u85e4\u4e00\u4eba\u3001\u5c71\u4e2d\u82f1\u58fd\u3001\u5cf6\u5d0e\u3000\u6df3\uff1a\u300c\u524d\u7acb\u817a\u691c\u8a3a\u5354\u8b70\u4f1a\u904b\u55b6\u59d4\u54e1\u4f1a\u30fb\u524d\u7acb\u817a\u304c\u3093\u64b2\u6ec5\u63a8\u9032\u59d4\u54e1\u4f1a\u5408\u540c\u4f1a\u8b70\u3000\u8a18\u9332\u96c6\u300d\uff1a\u524d\u7acb\u817a\u304c\u3093\u691c\u8a3a\u7814\u7a76\u73ed\uff08\u7530\u4e2d\u73ed\uff09\u5e73\u6210\uff11\uff16\u5e74\u5ea6\u7d50\u679c\u5831\u544a. \u6ccc\u5c3f\u5668\u5916\u79d1; 22(8):1097-1102, 2009.<\/li>\n
  30. \u5185\u85e4\u8aa0\u4e8c\u3001\u7b67\u3000\u5584\u884c\u3001\u9234\u6728\u548c\u6d69\u3001\u53e4\u8cc0\u5bdb\u53f2\u3001\u821b\u68ee\u76f4\u54c9\u3001\u8d64\u5009\u529f\u4e00\u90ce\u3001\u5ddd\u5cf6\u6e05\u9686\u3001\u6c96\u539f\u5b8f\u6cbb\u3001\u4f0a\u85e4\u4e00\u4eba\uff1a\u524d\u7acb\u817a\u304c\u3093\u691c\u8a3a\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\uff1a2010\u5e74\u5897\u88dc\u7248,\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7de8; \u91d1\u539f\u51fa\u7248, 2009.<\/li>\n
  31. \u9234\u6728\u548c\u6d69\uff1a\u300c\u524d\u7acb\u817a\u764c\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f32006\u5e74\u7248\u300d\u306e\u6982\u8981. \u65e5\u672c\u4eba\u9593\u30c9\u30c3\u30af\u5b66\u4f1a\u8a8c; 23(5):1005-1023, 2009.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Ito K\uff1aProstate-specific antigen-based screening for prostate cancer :Evidence, controversies and future perspe […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-26","post","type-post","status-publish","format-standard","hentry","category-achievements"],"_links":{"self":[{"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/posts\/26","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=26"}],"version-history":[{"count":2,"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/posts\/26\/revisions"}],"predecessor-version":[{"id":1306,"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/posts\/26\/revisions\/1306"}],"wp:attachment":[{"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=26"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=26"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=26"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}